Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor

被引:17
作者
Volotinen, Marjo [2 ,3 ]
Maenpaa, Jukka [3 ]
Kautiainen, Hannu [4 ]
Tolonen, Ari [5 ]
Uusitalo, Jouko [5 ]
Ropo, Auli [3 ]
Vapaatalo, Heikki [2 ]
Aine, Esko [1 ]
机构
[1] Tampere Univ Hosp, Dept Eye Ear & Oral Dis, Tampere 33521, Finland
[2] Univ Helsinki, Inst Biomed, Helsinki, Finland
[3] Santen Oy, Tampere, Finland
[4] Medcare Oy, Aanekoski, Finland
[5] Novamass Ltd, Oulu, Finland
关键词
Timolol; Aqueous humor; Hydrogel; GLAUCOMA; EFFICACY; METABOLISM; SAFETY; EYE;
D O I
10.1016/j.ejps.2008.10.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ophthalmic timolol has been used for decades in the treatment of glaucoma and ocular hypertension, traditionally in aqueous 0.5% eye drops. Recently a timolol 0.1% hydrogel has been developed to improve systemic safety. The aim of the present study was to compare aqueous humor timolol concentrations after administration of 0.1% hydrogel and aqueous 0.5% timolol in patients scheduled for a cataract operation. The concentration in the aqueous humor was 210 +/- 175 ng/ml (mean +/- SD.) 2 h after administration of timolol 0.1% hydrogel and 538 +/- 304ng/ml after aqueous 0.5% timolol. In the aqueous 0.5% timolol group more patients had unnecessarily high concentrations of timolol in the aqueous humor. beta(1)-receptors and beta(2)-receptors were practically 100% occupied after administration of both products. The hydrogel proved to be an excellent formulation in giving smaller inter-individual variation in penetration of timolol into the aqueous humor. Only a weak correlation was seen between corneal thickness and the aqueous humor concentration of timolol in the aqeuous 0.5% timolol group. In conclusion, in contrast to the conventional aqueous 0.5% timolol, 0.1% timolol hydrogel caused only slight inter-individual variation in timolol concentration in the aqueous humor. (c) 2008 Published by Elsevier B.V.
引用
收藏
页码:292 / 296
页数:5
相关论文
共 19 条
[1]  
[Anonymous], 2003, TERM GUID GLAUC
[2]   CONCENTRATION OF TIMOLOL IN AQUEOUS-HUMOR [J].
BLANKSMA, LJ .
DOCUMENTA OPHTHALMOLOGICA, 1991, 78 (3-4) :255-258
[3]   OCULAR BETA-BLOCKERS IN GLAUCOMA MANAGEMENT - CLINICAL PHARMACOLOGICAL ASPECTS [J].
BROOKS, AMV ;
GILLIES, WE .
DRUGS & AGING, 1992, 2 (03) :208-221
[4]   Associations between elevated intraocular pressure and glaucoma, use of glaucoma medications, and 5-year incident cataract - The Blue Mountains eye study [J].
Chandrasekaran, S ;
Cumming, RG ;
Rochtchina, E ;
Mitchell, P .
OPHTHALMOLOGY, 2006, 113 (03) :417-424
[5]   Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men [J].
Dickstein, K ;
Aarsland, T .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 121 (04) :367-371
[6]   Topical ocular hypotensive medication and lens opacification: Evidence from the ocular hypertension treatment study [J].
Herman, David C. ;
Gordon, Mae O. ;
Beiser, Julia A. ;
Chylack, Leo T., Jr. ;
Lamping, Kathleen A. ;
Schein, Oliver D. ;
Soltau, Joern B. ;
Kass, Michael A. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (05) :800-810
[7]   Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops [J].
Korte, JM ;
Kaila, T ;
Saari, KM .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2002, 240 (06) :430-435
[8]   Risk factors for incident nuclear opacities [J].
Leske, MC ;
Wu, SY ;
Nemesure, B ;
Hennis, A .
OPHTHALMOLOGY, 2002, 109 (07) :1303-1308
[9]   Efficacy of a novel hydrogel formulation in human volunteers [J].
Mayer, H ;
vonderOhe, N .
OPHTHALMOLOGICA, 1996, 210 (02) :101-103
[10]   Timolol 0.1% gel (Nyogel 0.1%®) once daily versus conventional timolol 0.5% solution twice daily:: A comparison of efficacy and safety [J].
Rouland, JF ;
Morel-Mandrino, P ;
Elena, PP ;
Polzer, H ;
Raj, PS .
OPHTHALMOLOGICA, 2002, 216 (06) :449-454